Indicateurs
1 Consultations de la notice
- Titre
- Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
- Créateurs - sans rôle
- E. Samalin - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceH. Senellart - Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FranceS. Thezenas - Biometrics Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceS. Jacquot - Medical Oncology, Centre de Cancérologie du Grand Montpellier, Montpellier, FranceS. Ellis - Radiotherapy Department, Centre Catalan d'Oncologie, Perpignan, FranceF. Khemissa - Department of Hepatology Gastroenterology, CH Perpignan, Saint Jean Hospital, Perpignan, FranceM. Ramdani - Gastroenterology Department, CH de Béziers, Béziers, FranceF. Portales - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceE. Assenat - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceT. Mazard - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, FranceL. Mineur - Institut Sainte CatherineM. Ychou - Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, France
- Détails de publication
- Annals of oncology, Vol.28, pp.v179-v179
- Éditeur
- Elsevier Ltd
- Identifiants
- 99141177409311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article